Learn about research studies and clinical trials conducted by the Division of Infectious Disease in the area of COVID-19.
- Lindsey Baden, MD: COVID-19 vaccines and controlled trials of convalescent plasma
- Amy Barczak, MD: Viral dynamics of SARS-CoV-2 infection
- Ruanne V. Barnabas, MBChB, DPhil: Clinical trials and economic modeling to increase access to prevention and treatment of infectious diseases
- Ingrid Bassett, MD, MPH: Increasing access to prevention and treatment for HIV and other infectious diseases
- Richelle Charles, MD: Assessment of antibody profiles in COVID-19 patients; national/international seroepidemiology studies of at-risk populations
- Andrea Ciaranello, MD: Clinical outcomes, epidemiology, and simulation modeling in the United States and resource-limited settings
- Scott Dryden-Peterson, MD MSc: Real world effectiveness studies; Disparities; Risk of severe outcomes
- Caitlin Dugdale, MD: Optimizing COVID-19 screening strategies in healthcare settings
- Marcia B. Goldberg, MD: High resolution analysis of immune responses to COVID-19
- Yonatan Grad, MD, PhD: COVID-19 epidemiology and the impact of interventions to slow and control spread
- Nicolas Issa, MD: Favipiravir for COVID-19
- Sanjat Kanjilal, MD: Performance characteristics of virologic and serologic assays for COVID-19
- Arthur Kim, MD: Clinical (hospitalized patients) and translational (immunology) research in COVID-19
- Camille Nelson Kotton, MD: Epidemiology of COVID-19 and immunocompromised hosts; impact of zanubrutinib on pulmonary distress in COVID-19
- Dan Kuritzkes, MD: Canakinumab for severe COVID-19; AT-527 (a novel purine analog) for moderate COVID-19
- Jonathan Li, MD, MMSc: HIV and SARS-CoV-2 drug resistance, persistence, and cure
- Anne Neilan, MD, MPH: COVID simulation modeling and pediatric COVID epidemiology
- Mark Poznansky, MD, PhD: Driving the development of a self-assembling vaccine candidate for protective immunity against SARS-CoV-2 and Influenza
- Edward Ryan, MD, DTM&H: Host-pathogen interactions, immune responses, and vaccine development for bacterial pathogens and COVID-19
- Erica Shenoy, MD, PhD: COVID-19 epidemiology, including nosocomial infection, healthcare worker infection, and levering informatics for infection prevention/control
- Mark Siedner, MD: COVID-19 surveillance in rural South Africa and impacts of control measures on older Ugandans
- Jatin Vyas, MD, PhD: Clinical significance of viral shedding from asymptomatic patients
- Stephen Walsh, MD: Hydroxychloroquine for patients with mild COVID-19
- Ann Woolley, MD: Observational study of patients with COVID-19 at BWH; tocilizumab for COVID-19
- Erica Shenoy, MD, PhD: COVID-19 epidemiology, including nosocomial infection, healthcare worker infection, and levering informatics for infection prevention/control
- Mark Siedner, MD: COVID-19 surveillance in rural South Africa and impacts of control measures on older Ugandans
- Jatin Vyas, MD, PhD: Clinical significance of viral shedding from asymptomatic patients
- Stephen Walsh, MD: Hydroxychloroquine for patients with mild COVID-19
- Ann Woolley, MD: Observational study of patients with COVID-19 at BWH; tocilizumab for COVID-19